The journal Biocentury Innovations has published an article on the study led by IRB Barcelona researchers Salvador Aznar Benitah and Fran Supek and first-authored by postdoctoral researcher Alexandra Avgustinova. The study has shown that increasing chromatin accessibility in cancer promotes tumour aggressiveness and does not reduce tumour mutation burden, as previously believed. The article refers to one of the main conclusions of the study, namely the need to evaluate the long-term effects of chromatin modifiers in tumour models before taking them into the clinic.
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 28 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).